Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report)'s stock had its "sell (e+)" rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.
Separately, Oppenheimer lowered their price target on Acrivon Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $15.00.
Read Our Latest Analysis on Acrivon Therapeutics
Acrivon Therapeutics Stock Performance
Acrivon Therapeutics stock traded up $0.06 during trading hours on Wednesday, reaching $1.97. 201,334 shares of the company's stock traded hands, compared to its average volume of 739,457. Acrivon Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $8.74. The firm has a market capitalization of $61.82 million, a price-to-earnings ratio of -0.87 and a beta of 1.80. The firm's 50 day moving average is $1.48 and its 200-day moving average is $1.49.
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.02. Analysts predict that Acrivon Therapeutics will post -2.49 EPS for the current year.
Institutional Trading of Acrivon Therapeutics
A number of large investors have recently bought and sold shares of ACRV. Nuveen LLC bought a new position in shares of Acrivon Therapeutics during the 1st quarter worth approximately $27,000. Quadrature Capital Ltd bought a new position in shares of Acrivon Therapeutics during the 2nd quarter worth approximately $26,000. Invesco Ltd. bought a new position in shares of Acrivon Therapeutics during the 1st quarter worth approximately $72,000. Wealthedge Investment Advisors LLC grew its stake in shares of Acrivon Therapeutics by 420.1% during the 1st quarter. Wealthedge Investment Advisors LLC now owns 56,467 shares of the company's stock worth $115,000 after acquiring an additional 45,610 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Acrivon Therapeutics during the 2nd quarter worth approximately $126,000. 71.62% of the stock is owned by institutional investors.
About Acrivon Therapeutics
(
Get Free Report)
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Acrivon Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.
While Acrivon Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.